From the left:
Peter Bush, David Fisher (Managing Director), Steven Kritzler, Maurie Stang (Chairman), Bernard Stang, Robert Waring (Company Secretary)
Maurie Stang
Non-Executive Chairman
Mr Stang is Chief Executive Officer of the Regional Health Care group of companies and of Novapharm Research. He has a 25 year track record of building and managing successful companies in the Australian healthcare market and extensive networks within the life-sciences and pharmaceutical sectors, both in Australia and internationally.
Since co-founding the Regional Health Care group, Mr Stang has been instrumental in building it into one of the region's leading healthcare product suppliers, with a key joint venture in the Australasian dental market and successful operating businesses across a range of medical, pharmaceutical and consumer healthcare sectors. Mr Stang is a Director and shareholder of Novapharm Research and of Nanosonics and is the founder of Gryphon Capital. Director since 2002; appointed Chairman 2002.
David Fisher
Managing Director
Dr Fisher has a first class honours degree in Rural Science, a PhD in Chemical Engineering from the Sydney University and a Masters degree in Applied Finance and Investments from Finsia.
Dr Fisher is a founding partner of Brandon Capital Partners, a leading Australian venture capital provider. He has over two decades of extensive operating experience in the biotechnology and healthcare industry in Australia and overseas. Dr Fisher was CEO of Peptech Limited (now part of Cephalon Inc. (Nasdaq:CEPH)). During this period Peptech grew from a start up to having R&D operations in Australia, the UK, the US and manufacturing operations in Denmark. Appointed Managing Director 2011
Steven Kritzler
Non-Executive Director (Since February 2005)
Acting Chief Executive Officer (to February 2005)
Mr Kritzler is the Technical Director of Novapharm Research. He has some 35 years experience in commercial R&D in the areas of pharmaceutical, medical, cosmetic and specialty industrial products. Under Mr Kritzler's technical direction, Novapharm Research has become a world-leader in infection control science.
Novapharm Research has become a world-leader in infection control science. Mr Kritzler has an M.Sc from UNSW in the field of Polymer Chemistry and holds a number of international patents. Mr Kritzler is a director and shareholder of a number of international patents. Mr Kritzler is a director and shareholder of Novapharm Research and of Nanosonics. Director since 2002.
Bernard Stang
Non-Executive Director
Mr Stang is co-founder and chairman of the Regional Health Care group of companies. He also chairs a number of private companies in the medical sector. Mr Stang manages a broad portfolio of investments in the private and listed sectors and has enjoyed over thirty years operational leadership in successful healthcare businesses.
Mr Stang is CEO of property development investment company Stangcorp Pty Ltd, which has been involved in various retail, commercial and industrial property prior to co-founding the Regional Health Care group of companies. Mr Stang is a director and shareholder of Novapharm Research and of Nanosonics. Director since 2002.
Peter Bush
Alternate Director and Chief Financial Officer
Mr Bush is the Chief Financial Officer of The Regional HealthCare Group and Gryphon Capital. RHCG is one of the region’s leading diversified healthcare product suppliers, with successful businesses across a range of medical, pharmaceutical, consumer healthcare and research & development sectors. GryphonCapital is an independent merchant bank that facilitates the financing and development of emerging health-care related entities. Mr. Bush begin his career working for 5 years at BDO, a global accounting and consulting firm, then has since spent a number of years working in industry. Mr Bush holds a number of private directorships and board positions.
Mr Bush holds a degree in Commerce from Macquarie University and a graduate diploma in Chartered Accounting from the Institute of Chartered Accountants in Australia. Mr. Bush is a member of the Institute of Chartered Accountants in Australia.
Robert Waring
Company Secretary
Mr Waring BEc, CA, FCIS, ASIA, FAICD was appointed to the position of Company Secretary in 2002. Mr Waring's experience has been gained over 33 years in financial and corporate roles including 15 years in company secretarial roles for ASX listed companies and 11 years as a director of an ASX listed company.
Mr Waring has had 23 years in industry and prior to that, nine years with an international firm of chartered accountants. He is a director of Oakhill Hamilton Pty Ltd, a company which provides secretarial and corporate advisory services to a range of listed and unlisted companies.
